Drug Discovery Featured Articles & Applications

  1. Lessons Learned While Taking Glioblastoma Drug From Bench To Clinic 4/9/2026

    MimiVax CEO Mike Ciesielski recounts the company's transition from academia to industry, hitting on topics like vendor partnerships, FDA conversations, and manufacturer selection. 

  2. Next‑Generation Omics: Latest Insights From A Growing Field 4/8/2026

    Experts share their latest discovery and translational research using multi-omics technologies at the NextGen Omics Spatial & Data conference in Boston.

  3. AI Drug Discovery Is Revealing The Preclinical Bottleneck 4/8/2026

    For the generative AI revolution in drug discovery to deliver on its promise, the industry needs more than better molecules, it needs a better pipeline architecture.

  4. Beyond Biologics: A Biophysical Approach To Crohn's Disease 4/2/2026

    Research into a nano-amorphous approach suggests a new breakthrough in Crohn’s management may come from a shift toward modulating the biophysical environment of the gut.

  5. Does TSLP Inhibition Signal The Next Wave Of Respiratory Biologics? 4/1/2026

    Thymic stromal lymphopoietin (TSLP) inhibition has firmly established itself as a strategy in respiratory disease. This article highlights some promising drug candidates and next-generation approaches.

  6. The Missing Data Set In Drug Discovery: Patient Experience As Decision Data 3/30/2026

    Drug discovery has become highly effective at capturing molecular detail, yet the experience of disease remains difficult to incorporate into early scientific decisions.

  7. Research Center Layout Helps Lower Barriers To Cross-Industry Collaboration 3/27/2026

    Discover how one research center, uniquely built for collaboration, enables the collection and analysis of high-quality specimens and data that will fuel both current and future research collaborations.

  8. What If The U.S. Government Stopped Funding Biotech? 3/23/2026

    It sets off a real tension – ideological, economic, even personal. But what would happen if the U.S. government cut direct financial support for “biotechnology research,” leaving it entirely to investors, private and public markets, and bigger pharma? "Our industry’s mind-meld says with no government largesse our biotech industry collapses," writes Chief Editor Louis Garguilo. It's an "outlandish hypothetical," but he asks for a few minutes to go through this. And he has help in making his case.

  9. What's Next For ADCs: How Combinations Will Help Define The Future Of Treatment 3/23/2026

    Insights gained from advancing ADC combination therapies in lung cancer are now shaping innovative approaches across multiple tumor types.

  10. 5 Takeaways From The Boston Open Science & Innovation Forum 3/20/2026

    The recent Boston Open Science & Innovation Forum was co-hosted by the Open Molecular Software Foundation (OMSF) and Ginkgo Datapoints.